ArticleHepatology (Baltimore, Md.)2019
Combination of Entecavir/Peginterferon Alfa-2a in Children With Hepatitis B e Antigen-Positive Immune Tolerant Chronic Hepatitis B Virus Infection.
Article in Hepatology (Baltimore, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 66 citations in OpenAlex.
- Younger age predicts increased HBsAg loss in children with chronic hepatitis B on antiviral therapy: A systematic review and meta-analysis.Infectious diseases & immunity · 2026Article
- High HBsAg clearance rate and viral dynamics in HBeAg-positive, ALT-normal children and adolescents with chronic HBV infection: results from the prospective sprout project.Emerging microbes & infections · 2025Article
- Review
- Scientific and medical evidence informing expansion of hepatitis B treatment guidelines.The lancet. Gastroenterology & hepatology · 2025Review
- Functional cure induced by tenofovir alafenamide plus peginterferon-alpha-2b in young children with chronic hepatitis B: a case series study.BMC infectious diseases · 2024Article
- Article
- Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B.Hepatology international · 2024Article
- Why is the functional cure rate of young children with chronic hepatitis B receiving antiviral therapy considerably high?Hepatology international · 2024Article
- [Study of the predictive role of serum HBV RNA on HBeAg serological conversion in children with chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- Functional Cure of Chronic Hepatitis B with Antiviral Treatment in Children having High-level Viremia and Normal or Mildly Elevated Serum Aminotransferase.Journal of clinical and translational hepatology · 2023Article
- Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023Article
- Immunostaining for hepatitis B viral antigens in liver: Association with clinical, biochemical, and virologic features of disease.Journal of gastroenterology and hepatology · 2023Article
- Review
- The scientific basis of combination therapy for chronic hepatitis B functional cure.Nature reviews. Gastroenterology & hepatology · 2023Review
- Efficacy of pegylated interferon α-2b plus entecavir therapy and predictors of treatment success in children with chronic hepatitis B.Frontiers in immunology · 2023Article
- Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients.Infection and drug resistance · 2023Article
- [Research progress on the characteristics of immune tolerant phase and antiviral therapy in children with chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Review
- [Clinical trials considerations for patients with immune-tolerant phase chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Review
- Clinical follow-up of patients with HBeAg positive chronic hepatitis B infection: A long-term observational study.Hepatology forum · 2022Article
- Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B.Hepatology communications · 2022Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 8 institutions in 2 countries.
Funding
Abstract
The optimal management strategy for children with immune-tolerant chronic hepatitis B virus (HBV) infection remains unknown. The purpose of this clinical trial was to determine the safety and efficacy of therapy with entecavir and peginterferon in a group of children in the immune-tolerant phase of HBV infection. Children with immune-tolerant features of chronic hepatitis B (CHB) received entecavir once-daily in a dose of 0.015 mg/kg (0.5 mg maximum) for 48 weeks; peginterferon alfa-2a (180 µg/1.73m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.